The Ongoing Journey of a Shigella Bioconjugate Vaccine

Shigellosis is a serious disease with a major impact, especially in low-income countries where mortality and morbidity are high. In addition, shigellosis among travelers and military personnel is a cause of significant morbidity and contributes to the increase in antimicrobial resistance. The World...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Vaccines (Basel) Ročník 10; číslo 2; s. 212
Hlavní autori: Martin, Patricia, Alaimo, Cristina
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland MDPI AG 29.01.2022
MDPI
Predmet:
Antibiotics
Antigens
Antimicrobial resistance
Bacteria
bioconjugate
Conjugates
Diarrhea
Drug resistance
Epidemics
Gram-positive bacteria
Health care
Immunogenicity
Low income areas
Microorganisms
Military personnel
Morbidity
O-antigen
Pathogens
Product development
Proteins
Public health
Review
Sanitation
Shigella
Shigellosis
Streptococcus infections
Vaccines
bioconjugate
O-antigen
vaccines
Shigella
ISSN:2076-393X, 2076-393X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Shigellosis is a serious disease with a major impact, especially in low-income countries where mortality and morbidity are high. In addition, shigellosis among travelers and military personnel is a cause of significant morbidity and contributes to the increase in antimicrobial resistance. The World Health Organization (WHO) considers the development of a Shigella vaccine a priority for public health. Over the past 60 years, several efforts to develop a Shigella vaccine have been pursued, without success. The principle of preventing shigellosis with a conjugate vaccine was demonstrated in the 1990′s, but this vaccine was not further developed. Bioconjugation is an innovative technology that allows the production of conjugate vaccines in a biological environment to preserve native immunogenic structures. In this review, we describe the journey of the bioconjugate Shigella vaccine, one of the most advanced clinical programs for a Shigella vaccine.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10020212